1. Anderluh G, Maček P. Cytolytic peptide and protein toxins from sea anemones (Anthozoa: Actiniaria). Toxicon 2002; 40:111-124.
2. Honma T, Shiomi K. Peptide toxins in sea anemones: structural and functional aspects. Mar Biotechnol 2006; 8:1-10.
3. Soletti RC, de Faria GP, Vernal J, Terenzi H, Anderluh G, Borges HL, et al. Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anti-Cancer Drugs 2008; 19:517-525 510.
4. Bellomio A, Morante K, Barlič A, Gutiérrez-Aguirre I, Viguera AR, González-Mañas JM. Purification, cloning and characterization of fragaceatoxin C, a novel actinoporin from the sea anemone Actinia fragacea. Toxicon 2009; 54:869-880.
5. Mechaly AE, Bellomio A, Gil-Cartón D, Morante K, Valle M, González-Mañas JM, et al. Structural Insights into the oligomerization and architecture of eukaryotic membrane pore-forming toxins. Structure 2011; 19:181-191.
6. Wang Y, Chua KL, Khoo HE. A new cytolysin from the sea anemone, Heteractis magnifica: isolation, cDNA cloning and functional expression. Biochim Biophys Acta 2000; 1478:9-18.
7. Anderluh G, Barlič A, Podlesek Z, Maček P, Pungerčar J, Gubenšek F, et al. Cysteine-scanning mutagenesis of an eukaryotic pore-forming toxin from sea anemone. Eur J Biochem 1999; 263:128-136.
8. Avila AD, de Acosta CM, Lage A. A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes. Int J Cancer 1988; 42:568-571.
9. Pederzolli C, Belmonte G, Serra MD, Macek P, Menestrina G. Biochemical and cytotoxic properties of conjugates of transferrin with equinatoxin II, a cytolysin from a sea anemone. Bioconjugate Chem 1995; 6:166-173.
10. Panchal RG, Cusack E, Cheley S, Bayley H. Tumor protease-activated, pore-forming toxins from a combinatorial library. Nat Biotech 1996; 14:852-856.
11. Patyar S, Joshi R, Byrav D, Prakash A, Medhi B, Das B. Review Bacteria in cancer therapy: a novel
experimental strategy. J Biomed Sci 2010; 17:21-30.
12. Michl P, Gress T. Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr Cancer Drug Targets 2004; 4:689-702.
13. Potrich C, Tomazzolli R, Dalla Serra M, Anderluh G, Malovrh P, Maček P, et al. Cytotoxic activity of a tumor protease-activated pore-forming toxin. Bioconjugate Chemistry 2005; 16:369-376.
14.Thorpe J, Sole-CAVA AM. Population structuring, gene dispersal and reproduction in the Actinia equina species group. Oceanogr Mar Biol 1999; 37:129.
15.Tanaka K, Caaveiro JM, Morante K, González-Mañas JM, Tsumoto K. Structural basis for self-assembly of a cytolytic pore lined by protein and lipid. Nat Commun 2015; 6.
16.Yang WS, Park SO, Yoon A-R, Yoo JY, Kim MK, Yun C-O, et al. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther 2006; 5:1610-1619.
17. Soletti RC, de Faria GP, Vernal J, Terenzi H, Anderluh G, Borges HL, et al. Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anticancer Drugs 2008; 19:517-525.
18. Parker MW, Feil SC. Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 2005; 88:91-142.
19. Koths K. Recombinant proteins for medical use: the attractions and challenges. Curr Opin Biotechnol 1995; 6:681-687.
20. Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Ann Rev Med 2015; 66:471-486.
21. Martino MM, Brkic S, Bovo E, Burger M, Schaefer DJ, Wolff T, et al. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. Front Bioeng Biotechnol 2015; 3.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
23. Anderluh G, Križaj I, Štrukelj B, Gubenšek F, Maček P, Pungerčar J. Equinatoxins, pore-forming proteins from the sea anemone Actinia equina, belong to a multigene family. Toxicon 1999; 37:1391-1401.